Click Here to Download MD/DNB General Medicine Curriculum:
https://drive.google.com/file/....d/1Edjjh9iymY5P4d12s

Download RAAONLINE App:
Android: https://play.google.com/store/....apps/details?id=com.
iOS: https://apps.apple.com/in/app/....raaonline/id15644092

Contact: +91 9994994266

MD/DNB General Medicine Package Features:
600+ Video lectures
30+ Expert Faculties
Full Harrison Based Video Lectures
General Medicine Curriculum Covered
Clinical Case Discussion
MCQ Discussions
NEET-SS Syllabus Included
Image Based Classes
Concept Based Classes
4000 MCQ's
10 Grand Exams
500+ Topic Slides

MD/DNB Harrison Based Teaching Specialties:
1. Pulmonology
2. Gastrointestinal System
3. Cardiology
4. Endocrine system
5. Nephrology
6. Neurology
7. Rheumatology
8. Hematology
9. Oncology
10. Infectious Diseases
11. Miscellaneous

Watch Harrison Based Teaching Demo Lectures:
Playlist Link: https://www.youtube.com/watch?v=y5LRsH6ke9U&list=PLArsyhQ0pyyLUOiVQsgBLcPXMR_LOImk9

MD/DNB General Medicine Specialties:
1. Anatomy, Physiology and Pathology of the heart
2. Approach to a Patient with Cardiovascular Disease
3. Coronary Artery Disease
4. Basic ECG
5. Advanced ECG
6. Blood Pressure Management
7. Clinical Case Discussion - Cardiovascular System
8. Clinical Case Discussion - Respiratory System
9. Clinical Case Discussion - Central Nervous System
10. Clinical Case Discussion - Medical Gastroenterology
11. Infectious Diseases
12. Master Class in Neurology
13. Nephrology
14. Rheumatology
15. Endocrinology
16. Diabetology
17. Hemato-Oncology
18. Sleep Medicine
19. MCQ's Discussions
20. Electrolyte and Fluid Balance

Watch MD/DNB General Medicine Demo Lectures Part 1:
Playlist Link: https://www.youtube.com/watch?v=mnbYTWurkBw&list=PLArsyhQ0pyyKWjI0Gsik1hNSezds5ZDn7

Watch MD/DNB General Medicine Demo Lectures Part 2:
Playlist Link: https://www.youtube.com/watch?v=O4xjOzCvWIs&list=PLArsyhQ0pyyKPQdyUQhdbHPnzxzV4gkHj

Click Here to Download Comprehensive Critical Care Medicine Curriculum: https://drive.google.com/file/....d/1oZjcnihiZPW1y8rum

Comprehensive Critical Care Medicine:
Specialties - 11
Video Lectures - 211
Test Series - 59
MCQ's - 1414
Presentations - 149
Reading Materials - 234
No.of Faculties - 50+

Comprehensive Critical Care Medicine Specialities:
1. Arterial Blood Gas
2. Clinical Nutrition
3. Critical Care Pearls
4. ECMO
5. Basic Echocardiogram
6. Ultrasound
7. Mechanical Ventilation
8. Electrolyte Disturbances & Fluid Balance
9. Basic & Advanced Hemodynamics
10. Advanced Echocardiogram
11. Infectious Disease

Watch Comprehensive Critical Care Medicine Demo Lectures:
Playlist Link: https://www.youtube.com/watch?v=njMiq5dOBO0&list=PLArsyhQ0pyyIaOXh0EzKTtsMNRBlSsc-b

Follow us on:
Facebook: https://www.facebook.com/Raaon....line-Certify-4448750
Instagram: https://www.instagram.com/raaonline_medinfopedia/
Twitter: https://twitter.com/Raaonline
LinkedIn: https://www.linkedin.com/in/ra....njith-karthekeyan-58

Professor Mohan is back with another episode of #MedSchoolMondays with #PROMO. Today PROMO will be introducing the topic of Diabetes Mellitus. Make sure to like the video, subscribe to the channel, and leave a comment below!

Follow Professor Mohan on Instagram @PROMOakaProfessorMohan

Click the links below for the most recent Endocrine videos:

Multiple Endocrine Neoplasia Syndromes
https://www.youtube.com/watch?v=DTyQFrcvos0

Pancreatic Tumours:
https://www.youtube.com/edit?o=U&video_id=U5ygIOIYtVY

Neuroblastoma:
https://www.youtube.com/watch?v=Ku_03VIgFNM

Pheochromocytoma
https://www.youtube.com/edit?o=U&video_id=seIUROt2A7I

Congenital Adrenal Hyperplasia:
https://www.youtube.com/watch?v=QTQLg1hPGiU&t=14s

Adrenal “sex” androgens:
https://www.youtube.com/watch?v=LxIN5VlkA2s

Cortisol Hormone Part 3: Adrenal Insufficiency
https://www.youtube.com/watch?v=MXP8TQHUa_8

Cortisol Hormone Part 2: Cushings Syndrome
https://www.youtube.com/edit?o=U&video_id=_rBxwvxjkcU

Cortisol Hormone Part 1: Introduction
https://www.youtube.com/watch?v=hSclkUd5j-s&t=25s

Parathyroid Hormone Part 3: Hypoparathyroidism
https://www.youtube.com/watch?v=I6E4D9_OD5g&t=30s

Parathyroid Hormone Part 2: Hyperparathyroidism
https://www.youtube.com/watch?v=nvZLVb26El4

Parathyroid Hormone Part 1 and Vitamin D:
https://www.youtube.com/edit?o=U&video_id=ZLwsBd6JkF0

Thyroid Hormone Part 4 - Thyroid Cancers:
https://www.youtube.com/watch?v=Djlx6O-sOUA&t=150s

Thyroid Hormone Part 3 - Hyperthyroidism:
https://www.youtube.com/watch?v=_rx4H_CZpV8

Thyroid Hormone Part 2 - Hypothyroidism:
https://www.youtube.com/watch?v=eo5P_6jZtzM

Thyroid Hormone Part 1:
https://www.youtube.com/watch?v=-2YK0HBtWRs

Growth Hormone:
https://www.youtube.com/watch?v=pzsRpSMK4bw&t=25s&spfreload=5

Syndrome of Inappropriate Antidiuretic Hormone (SIADH):
https://www.youtube.com/watch?v=U1kLv4qXesE

Antidiuretic hormone (ADH) and Diabetes Insipidus:
https://www.youtube.com/watch?v=HMHIPXEqcBE

Prolactin Regulation:
https://www.youtube.com/watch?v=3z0cbHrtJ5Q&t=25s

Introduction to the Endocrine System:
https://www.youtube.com/watch?v=HmseXN4kkkg

Music credits: Kevin MacLeod - “If I had a chicken”

Please click here to see the Prescribing Information—https://bit.ly/2OiAhVt.

Please click here to see the Important Safety Information—https://bit.ly/2PnElzx.

Hear from GLP-1 expert, Dr Richard Pratley, as he explains the SUSTAIN 7 Trial results and how Ozempic® (semaglutide) injection 0.5 mg or 1 mg compared to Trulicity® in reducing and controlling A1C.

Learn more about the SUSTAIN 7 Trial—https://bit.ly/3PsegiJ.

Important Safety Information

BOXED WARNING: RISK OF THYROID C-CELL TUMORS
• In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
• Ozempic® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic®.

Indications and Limitations of Use

Ozempic® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and established CV disease.
• Ozempic® has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
• Ozempic® is not indicated for use in patients with type 1 diabetes mellitus.

Important Safety Information (cont’d)

Contraindications
• Ozempic® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a hypersensitivity reaction to semaglutide or to any of the excipients in Ozempic®. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Ozempic®.

Warnings and Precautions
• Risk of Thyroid C-Cell Tumors: Patients should be referred to an endocrinologist for further evaluation if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
• Pancreatitis: Acute and chronic pancreatitis have been reported in clinical studies. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Ozempic® promptly, and if pancreatitis is confirmed, do not restart.
• Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic® (3.0%) compared with placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
• Never Share an Ozempic® Pen Between Patients: Ozempic® pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens.
• Hypoglycemia: Patients receiving Ozempic® in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
• Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of Ozempic® in patients reporting severe adverse gastrointestinal reactions.

Click here: https://bit.ly/2PnElzx, or see video above for additional Important Safety information.